Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 14/20 | 0.47 |
| ▸ | GAA | P10253 | 14/20 | 0.47 |
| ▸ | SI | P14410 | 14/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123976 | 0.81 | CBFB (0.43) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL4356906 | 0.81 | PSMB8 (0.49) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL23123180 | 0.80 | SMN1; SMN2 (0.54) | CBFBALDH1A1ADORA2A | |
| SCHEMBL353891 | 0.77 | PARP1 (0.56) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL28790557 | 0.77 | PARP1 (0.54) | ALDH1A1 | |
| SCHEMBL1297983 | 0.76 | KDM4E (0.54) | — | |
| Bromide SCHEMBL5318091 | 0.76 | PARP1 (0.55) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL11884640 | 0.76 | ALDH1A1 (0.56) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4919548 | 0.75 | DDAH1 (0.55) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL30518181 | 0.75 | DDAH1 (0.55) | CBFBMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | CBFB 565/4885MGAM 4855/4885GAA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.